Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.62 - $3.71 $20,436 - $28,938
-7,800 Reduced 98.73%
100 $0
Q2 2024

Aug 14, 2024

BUY
$2.65 - $3.92 $795 - $1,176
300 Added 3.95%
7,900 $24,000
Q1 2024

May 15, 2024

BUY
$2.59 - $4.65 $9,065 - $16,275
3,500 Added 85.37%
7,600 $26,000
Q4 2023

Feb 14, 2024

BUY
$1.54 - $3.37 $4,004 - $8,762
2,600 Added 173.33%
4,100 $12,000
Q3 2023

Nov 14, 2023

SELL
$1.5 - $3.75 $49,650 - $124,125
-33,100 Reduced 95.66%
1,500 $2,000
Q2 2023

Aug 14, 2023

BUY
$2.21 - $4.43 $3,315 - $6,645
1,500 Added 4.53%
34,600 $96,000
Q1 2023

May 15, 2023

BUY
$3.81 - $6.76 $113,538 - $201,448
29,800 Added 903.03%
33,100 $137,000
Q4 2022

Feb 14, 2023

BUY
$4.26 - $6.84 $14,058 - $22,572
3,300 New
3,300 $15,000

Others Institutions Holding CDXS

About CODEXIS, INC.


  • Ticker CDXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,494,100
  • Market Cap $302M
  • Description
  • Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protei...
More about CDXS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.